Increased signal transducer and activator of transcription 3 (STAT3) and decreased cyclin D1 in recurrent astrocytic tumours compared with paired primary astrocytic tumours

Journal of International Medical Research

Volumn 39, Issue 6, 2011, Pages 2103-2109

  Zhang, K ^a   Pang, B ^b   Xin, T ^a   Hou, X ^a   Jia, J ^a   Feng, B ^a   Meng, L ^b   Xu, S ^a   Pang, Q ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Cyclin d1; Progression free survival; Radiotherapy; Recurrent astrocytic tumour; Signal transducer and activator of transcription 3 (STAT3)

Indexed keywords

CYCLIN D1; STAT3 PROTEIN; TUMOR MARKER;

ADULT; ARTICLE; ASTROCYTOMA; CANCER RADIOTHERAPY; CANCER SURGERY; CCND1 GENE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MOLECULAR PATHOLOGY; ONCOGENE; PREDICTIVE VALUE; PRIMARY TUMOR; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; TUMOR RECURRENCE;

EID: 84555204273     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001103900606     Document Type: Article

References (33)

1. Germain D, Frank DA: Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy. Clin Cancer Res 2007; 13: 5665-5669.
2. Tashiro E, Tsuchiya A, Imoto M: Functions of cyclin D1 as an oncogene and regulation of cyclin D1 expression. Cancer Sci 2007; 98: 629-635.
3. Louis DN, Ohgaki H, Wiestler OD, et al: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114: 97-109.
4. Wen PY, Kesari S: Malignant gliomas in adults. N Engl J Med 2008; 359: 492-507.
5. Mizoguchi M, Betensky RA, Batchelor TT, et al: Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival. J Neuropathol Exp Neurol 2006; 65: 1181-1188.
6. Iwamaru A, Szymanski S, Iwado E, et al: A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 2007; 26: 2435-2444.
7. Senft C, Priester M, Polacin M, et al: Inhibition of the JAK-2/STAT3 signaling pathway impedes the migratory and invasive potential of human glioblastoma cells. J Neurooncol 2011; 101: 393-403.
8. Kyritsis AP, Levin VA: An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting. Cancer Chemother Pharmacol 2011; 67: 971-983.
9. Kang SH, Yu MO, Park KJ, et al: Activated STAT3 regulates hypoxia-induced angiogenesis and cell migration in human glioblastoma. Neurosurgery 2010; 67: 1386-1395.
10. Rahaman SO, Harbor PC, Chernova O, et al: Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene 2002; 21: 8404-8413.
11. Zhang L, Alizadeh D, Van Handel M, et al: Stat3 inhibition activates tumor macrophages and abrogates glioma growth in mice. Glia 2009; 57: 1458-1467.
12. Konnikova L, Kotecki M, Kruger MM, et al: Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells. BMC Cancer 2003; 3: 23.
13. Pectasides E, Egloff AM, Sasaki C, et al: Nuclear localization of signal transducer and activator of transcription 3 in head and neck squamous cell carcinoma is associated with a better prognosis. Clin Cancer Res 2010; 16: 2427-2434.
14. Shah NG, Trivedi TI, Tankshali RA, et al: Stat3 expression in oral squamous cell carcinoma: association with clinicopathological parameters and survival. Int J Biol Markers 2006; 21: 175-183.
15. Wang YC, Zheng LH, Ma BA, et al: Clinical value of signal transducers and activators of transcription 3 (STAT3) gene expression in human osteosarcoma. Acta Histochem 2011; 113: 402-408.
16. Min H, Wei-hong Z: Constitutive activation of signal transducer and activator of transcription 3 in epithelial ovarian carcinoma. J Obstet Gynaecol Res 2009; 35: 918-925.
17. Ryu K, Choy E, Yang C, et al: Activation of signal transducer and activator of transcription 3 (Stat3) pathway in osteosarcoma cells and overexpression of phosphorylated-Stat3 correlates with poor prognosis. J Orthop Res 2010; 28: 971-978.
18. Takemoto S, Ushijima K, Kawano K, et al: Expression of activated signal transducer and activator of transcription-3 predicts poor prognosis in cervical squamous-cell carcinoma. Br J Cancer 2009; 101: 967-972.
19. Yakata Y, Nakayama T, Yoshizaki A, et al: Expression of p-STAT3 in human gastric carcinoma: significant correlation in tumour invasion and prognosis. Int J Oncol 2007; 30: 437-442.
20. Monnien F, Zaki H, Borg C, et al: Prognostic value of phosphorylated STAT3 in advanced rectal cancer: a study from 104 French patients included in the EORTC 22921 trial. J Clin Pathol 2010; 63: 873-878.
21. Mizoguchi M, Betensky RA, Batchelor TT, et al: Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival. J Neuropathol Exp Neurol 2006; 65: 1181-1188.
22. Arato-Ohshima T, Sawa H: Over-expression of cyclin D1 induces glioma invasion by increasing matrix metalloproteinase activity and cell motility. Int J Cancer 1999; 83: 387-392.
23. Arber N, Doki Y, Han EK, et al: Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Res 1997; 57: 1569-1574.
24. Chen B, Zhang XY, Zhang YJ, et al: Antisense to cyclin D1 reverses the transformed phenotype of human gastric cancer cells. World J Gastroenterol 1999; 5: 18-21.
25. Cavalla P, Dutto A, Piva R, et al: Cyclin D1 expression in gliomas. Acta Neuropathol 1998; 95: 131-135.
26. Zhang X, Zhao M, Huang AY, et al: The effect of cyclin D expression on cell proliferation in human gliomas. J Clin Neurosci 2005; 12: 166-168.
27. Chakrabarty A, Bridges LR, Gray S: Cyclin D1 in astrocytic tumours: an immunohisto-chemical study. Neuropathol Appl Neurobiol 1996; 22: 311-316.
28. Yang SX, Hewitt SM, Steinberg SM, et al: Expression levels of eIF4E, VEGF, and cyclin D1, and correlation of eIF4E with VEGF and cyclin D1 in multi-tumor tissue microarray. Oncol Rep 2007; 17: 281-287.
29. Büschges R, Weber RG, Actor B, et al: Amplification and expression of cyclin D genes (CCND1, CCND2 and CCND3) in human malignant gliomas. Brain Pathol 1999; 9: 435-443.
30. Abdullah JM, Ahmad F, Ahmad KA, et al: Molecular genetic analysis of BAX and cyclin 'D1 genes in patients with malignant glioma. Neurol Res 2007; 29: 239-242.
31. Milas L, Akimoto T, Hunter NR, et al: Relationship between cyclin D1 expression and poor radioresponse of murine carcinomas. Int J Radiat Oncol Biol Phys 2002; 52: 514-521.
32. Hwang CF, Cho CL, Huang CC, et al: Loss of cyclin D1 and p16 expression correlates with local recurrence in nasopharyngeal carcinoma following radiotherapy. Ann Oncol 2002; 13: 1246-1251.
33. Jayasurya R, Francis G, Kannan S, et al: p53, p16 and cyclin D1: molecular determinants of radiotherapy treatment response in oral carcinoma. Int J Cancer 2004; 109: 710-716.